Sara Hurvitz, MD, FACP, Senior Vice President and director of the Clinical Research at Fred Hutchinson Cancer Center, speaks to SABCS Program Director Kate Lathrop, MD, about the primary analysis of HER2CLIMB-02: Tucatinib and Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer.
Estimated Read Time:
1 minute
SABCS Snippets: Primary analysis of HER2CLIMB-02
Share
Recent Posts
-
December 15, 2025
-
December 15, 2025
-
FDA session offers closer look at approval process for HR-positive metastatic breast cancer therapies
December 15, 2025 -
December 15, 2025
